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Methods for Population-Adjusted Indirect
Comparisons in Health Technology Appraisal
David M. Phillippo, Anthony E. Ades, Sofia Dias, Stephen Palmer,
Keith R. Abrams, and Nicky J. Welton
Abstract
Standard methods for indirect comparisons and network meta-analysis are based on aggregate data, with the key
assumption that there is no difference between the trials in the distribution of effect-modifying variables. Methods
which relax this assumption are becoming increasingly common for submissions to reimbursement agencies, such as
the National Institute for Health and Care Excellence (NICE). These methods use individual patient data from a sub-
set of trials to form population-adjusted indirect comparisons between treatments, in a specific target population.
Recently proposed population adjustment methods include the Matching-Adjusted Indirect Comparison (MAIC) and
the Simulated Treatment Comparison (STC). Despite increasing popularity, MAIC and STC remain largely untested.
Furthermore, there is a lack of clarity about exactly how and when they should be applied in practice, and even
whether the results are relevant to the decision problem. There is therefore a real and present risk that the assumptions
being made in one submission to a reimbursement agency are fundamentally different to—or even incompatible
with—the assumptions being made in another for the same indication. We describe the assumptions required for
population-adjusted indirect comparisons, and demonstrate how these may be used to generate comparisons in any
given target population. We distinguish between anchored and unanchored comparisons according to whether a com-
mon comparator arm is used or not. Unanchored comparisons make much stronger assumptions, which are widely
regarded as infeasible. We provide recommendations on how and when population adjustment methods should be
used, and the supporting analyses that are required to provide statistically valid, clinically meaningful, transparent and
consistent results for the purposes of health technology appraisal. Simulation studies are needed to examine the prop-
erties of population adjustment methods and their robustness to breakdown of assumptions.
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Standard methods for indirect comparisons1 and net-
work meta-analysis2 (NMA) (see Dias et al.3 for a com-
prehensive guide) are based on aggregate data, and
assume that the distributions of effect-modifying vari-
ables do not differ between studies. Methods that relax
this assumption to form ‘‘population-adjusted indirect
comparisons’’ are becoming increasingly common for
submissions to reimbursement agencies, such as the
National Institute for Health and Care Excellence
(NICE). Ideally, we would have individual patient data
(IPD) from all studies to fully adjust for patient differ-
ences using network meta-regression, as aggregate data
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network meta-regression has low power to detect or
adjust for covariates and is susceptible to ecological
bias.4,5 However, it is rarely the case that full IPD are
available. In particular, a very common scenario is when
a company has IPD on its own trial but only published
aggregate data on their competitor’s trial, typically con-
sisting of average treatment effects and summary patient
characteristics (e.g., mean and standard deviation for
continuous characteristics, and proportions for binary/
categorical). Population adjustment methods use the
available IPD to adjust for between-trial imbalances in
the distribution of observed covariates. These methods
cannot adjust for differences in, for example, treatment
administration, co-treatments, or treatment switching, as
these are perfectly confounded with treatment. We focus
on 2 recently proposed methods: Matching-Adjusted
Indirect Comparison (MAIC)6–8 and Simulated Treatment
Comparison (STC).7,9 MAIC and STC are not the only
possible approaches to population adjustment; we outline
some alternatives in the discussion.
This paper is based on a Technical Support Document
prepared for the NICE Decision Support Unit, available
from http://www.nicedsu.org.uk/.10We begin by introdu-
cing the population adjustment scenario. We then
describe MAIC and STC in detail, and clearly set out
their assumptions and properties. We propose the shared
effect modifier assumption which, if justified, may be
used to transport indirect comparisons into any target
population. Recommendations on the use of population
adjustment methods in technology appraisal are then
given, with a particular focus on reproducibility, consis-
tency, and transparency, whilst minimizing bias and max-
imizing precision.
Overview of the Problem
We focus exposition on a simple indirect comparison
between 2 treatments based on 2 studies; although, our
recommendations and many of the methods are general-
izable to comparisons involving more treatments or stud-
ies.10 We distinguish between population adjustment
methods to make ‘‘anchored’’ indirect comparisons,
where the evidence is connected by a common compara-
tor, and ‘‘unanchored’’ indirect comparisons, where the
evidence is disconnected due to a lack of a common com-
parator or single-arm studies. We begin by describing the
anchored scenario; the unanchored scenario then follows
simply (albeit, with very different assumptions; see the
overview in the following section). We make a clear and
necessary distinction between prognostic variables and
effect modifiers: prognostic variables are covariates that
affect the outcome whereas effect modifiers (also known
as predictive variables11) are covariates that alter the
effect of treatment as measured on a given scale. Effect
modifiers are not necessarily also prognostic variables,
and may be specific to each treatment. Effect modifier
status on one scale does not necessarily imply effect
modifier status on another scale. We assume internal
validity of the studies included in the analysis, so that the
studies provide unbiased estimates of treatment effects in
their respective sample populations.
Consider one AB trial, for which the analyst has IPD,
and one AC trial, for which only published aggregate
data are available. We wish to estimate a comparison of
the effects of treatments B and C on an appropriate scale
in some target population P, denoted by the parameter
dBC(P). Within the AB trial population, there are para-
meters mA(AB), mB(AB) and mC(AB) representing the expected
outcome on each treatment (including for treatment C,
which was not studied in the AB trial). The AB trial pro-
vides estimators YA(AB) and YB(AB) of mA(AB) and mB(AB),
respectively, which are the summary outcomes; for exam-
ple, the probability of success, on each arm (note that
mC(AB) is not estimated by the AB trial). There is a parallel
system of parameters (mA(AC), mB(AC), mC(AC)) and estima-
tors (YA(AC), YC(AC)) in the AC trial.
Having selected a suitable scale, for example, a logit,
log, risk difference, or mean difference scale, we form
estimators D^AB(AB) and D^AC(AC) of the population-specific
relative treatment effects dAB(AB) and dAC(AC) in each trial
using the appropriate link function g ð Þ:
D^AB(AB)= g YB(AB)
 
 g YA(AB)
 
,
D^AC(AC)= g YC(AC)
 
 g YA(AC)
 
: ð1Þ
Standard methods for indirect comparisons make the
assumption that there is no difference in the distribution
of trial-level effect modifiers, specific to the chosen scale,
between the populations in the AB and AC trials or the
target population P, so that population-specific relative
treatment effects are equal across populations:
dAB(AB)= dAB(AC)= dAB(P) and dAC(AB)= dAC(AC)= dAC(P).
Under this assumption, the standard indirect comparison
estimator of the relative effect dBC(P) is
D^BC(P)= D^AC(AC)  D^AB(AB); ð2Þ
which takes account of the fact that patients are only ran-
domized within trials.1
The final step is to apply these relative effects to a
specified target population P in which the summary abso-
lute effect (such as the mean change from baseline, or
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probability of response) of treatment A is YA(P). We can
now estimate the summary absolute effects of treatments
A, B, C in the target population, mA(P), mB(P), mC(P),
which have estimators
YA(P), Y^B(P)= g
1 g YA(P)
 
+ D^AB(P)
 
,
Y^C(P)= g
1 g YA(P)
 
+ D^AC(P)
 
: ð3Þ
Suppose that in each trial we have information on a
common set of covariates X. Between-trial differences in
the distribution of prognostic variables that are not
effect modifiers do not affect inference, because the
within-trial randomization means that they do not
impact on the relative treatment effects (assuming that
the sample size is sufficiently large). Note that effect
modifiers XEM , a subset of X, are assumed to have an
additive effect on the transformed scale, such that, at
any given value of XEM , the conditional relative effect is
dAB X
EM
 
= dAB 0ð Þ+g
T
X
EM , conceptualized as an
‘‘intercept’’ term (the relative effect dAB 0ð Þ at X
EM = 0)
plus an interaction effect, gTXEM .
If there are effect modifiers and if these are distributed
differently between the populations, the relative treat-
ment effects dAB(AB), dAC(AC) that can be estimated directly
from each trial are only valid for a population with the
distribution of effect modifiers observed in that trial. For
example, we would have estimates d^AB(AB) in the AB popu-
lation and d^AC(AC) in the AC population, but it would not
be possible to identify a coherent set of estimates, either
for the population represented in the AB trial
d^AB(AB), d^AC(AB), d^BC(AB)= d^AC(AB)  d^AB(AB);
or for the population represented in the AC trial
d^AB(AC), d^AC(AC), d^BC(AC)= d^AC(AC)  d^AB(AC);
or, indeed, for any other target population.
The premise of MAIC and STC is to ‘‘adjust for’’
between-trial differences in ‘‘baseline characteristics’’, in
order to identify a coherent set of estimates where stan-
dard methods of indirect comparison cannot. Both meth-
ods use IPD on the AB trial to form predictors
Y^A(AC), Y^B(AC) of the summary outcomes that would be
observed on treatments A and B in the AC trial if the
AB trial population was the same as the AC trial
population.
The predicted outcomes Y^A(AC), Y^B(AC) may then be
used in 2 ways. First, relative effects may be estimated
by an anchored indirect comparison:
D^BC(AC)= g
YC(AC)
 
 g YA(AC)
  
 g Y^B(AC)
 
 g Y^A(AC)
  
: ð4Þ
Alternatively, an unanchored indirect comparison can
generated:7,8
D^BC(AC)= g
YC(AC)
 
 g Y^B(AC)
 
: ð5Þ
The anchored indirect comparison should always be
preferred in a connected network as it respects the ran-
domization within studies, whereas the unanchored indi-
rect comparison requires much stronger assumptions
that are very hard to meet. If the treatment network is
disconnected or contains single-arm studies, then there is
no common comparator arm through which to make an
anchored indirect comparison, and we are obliged to rely
on an unanchored indirect comparison.
MAIC and STC are both based upon methods
that date back several decades—propensity score reweight-
ing and regression adjustment, respectively—and are dis-
cussed extensively in the literature on standardization,12–15
generalization,16–20 and calibration.21–24 Like MAIC and
STC, these methods have been aimed at mapping the
absolute and relative effects observed in one population
into effects that would be predicted in another, in both
randomized and observational study settings. The novel
aspect of MAIC and STC is to provide indirect compari-
sons when IPD are only available in the AB trial, with
aggregate data in the AC trial along with summary infor-
mation on the covariate distribution. If individual patient
data are available on both the AB and AC studies, a net-
work meta-regression using IPD is the gold-standard
approach.4;5;25-27 Ideally, the full joint distribution of cov-
ariates X is known or can be obtained from conditional
distributions, but frequently in practice only the marginal
mean and standard deviation of each covariate are known.
Due to the lack of IPD from the AC trial, standard
approaches to fitting both propensity score and outcome
models cannot be used. We outline both MAIC and STC
approaches below. A worked example of MAIC and STC
as conforming to our recommendations is provided in the
online Appendix.
Overview of Methods for Population Adjustment
with Limited IPD
Population Reweighting Methods
MAIC is a reweighting method similar to inverse pro-
pensity score weighting14 and non-parametric likelihood
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reweighting,23 which allows the propensity score logistic
regression model to be estimated without IPD in the AC
population. The mean outcomes mt(AC) on treatment
t=A,B in the AC target population are estimated by
taking a weighted average of the outcomes Yit(AB) of the
Nt(AB) individuals in arm t of the AB population,
Y^t(AC)=
PNt(AB)
i= 1
Yit(AB)wit
PNt(AB)
i= 1
wit
; ð6Þ
where the weight wit assigned to the i-th individual receiv-
ing treatment t is equal to the odds of being enrolled in
the AC trial v. the AB trial. The weights are estimated
using logistic regression as log witð Þ=a0+a
T
1
Xit, where
Xit is the covariate vector for the i-th individual receiving
treatment t; however, the regression parameters are not
estimable using standard methods due to the lack of IPD
in the AC trial. Signorovitch et al.6 use the method of
moments to estimate a^1 so that the weights exactly bal-
ance the mean covariate values (and any included higher
order terms; for example, squared covariate values to
balance the variance) between the weighted AB popula-
tion and the AC population. When X(AC)= 0,
Signorovitch et al. show that this is equivalent to minimiz-
ing
P
t=A,B
PNt(AB)
i= 1 exp a
T
1
Xit
 
. The estimator in equation
(6) is then equal to
Y^t(AC)=
PNt(AB)
i= 1
Yit(AB)exp a^
T
1
Xit
 
PNt(AB)
i= 1
exp a^T
1
Xit
  ;
noting that exp a^0ð Þ cancels from the top and bottom of
the fraction. Anchored and unanchored indirect compar-
isons are then formed using equations (4) and (5), respec-
tively. Although MAIC can be used to facilitate indirect
comparisons on any scale, the MAIC literature almost
exclusively performs comparisons on the natural out-
come scale (i.e., with g ð Þ the identity function).
Typically, standard errors for MAIC estimates are calcu-
lated using a robust sandwich estimator28 (see the
Appendix of Signorovitch et al.6). Sandwich estimators
are derived empirically from the data, and account for
the fact that the weights are estimated rather than fixed
and known. Signorovitch et al.6 suggest reporting the
effective sample size (ESS) of the pseudo-population
formed by weighting the AB population, approximated
by
ESS=
P
t=A,B
PNt(AB)
i= 1 w^it
 2P
t=A,B
PNt(AB)
i= 1 w^
2
it: ð7Þ
This approximate ESS is only accurate if the weights are
fixed and known, or if they are uncorrelated with the
outcome—neither of which is true here. As such, this
approximation is likely to be an underestimation of the true
ESS.29 Small ESS indicates that the weights are highly vari-
able due to a lack of population overlap, and that the
resulting estimate may be unstable. The distribution of
weights themselves should also be examined directly, to
diagnose issues with a lack of population overlap and to
highlight any overly influential individuals. It is not possible
to apply traditional propensity score tools for ‘‘balance
checking’’ here,19,20 as propensity scores are only estimated
for the AB trial, and the method of moments, by definition,
ensures covariate balance (at least to the level of informa-
tion published in the AC trial).
Another form of population reweighting is based on
entropy balancing,30 and was first suggested for treatment
effect calibration by Belger et al.31,32 The approach is identi-
cal to standard MAIC except that the weights are addition-
ally constrained to be as close to each other as possible;
entropy balancing methods should thus have equal or
reduced standard error compared to MAIC, whilst achiev-
ing the same reduction in bias. Different schemes for apply-
ing weights have also been proposed.31,32 These involve
splitting apart trial arms and balancing covariate distribu-
tions separately between the control arms (A) and between
the treatment arms (B and C) in the IPD and aggregate
populations. The properties of such ‘‘splitting’’ approaches
in comparison with more typical population reweighting
are largely unknown, and require further investigation.
Outcome Regression Methods
Simulated Treatment Comparison (STC) is a modifica-
tion of covariate adjustment,21 which fits an outcome
model using the IPD in the AB trial:
g mt(AB) Xð Þ
 
=b0+b
T
1
X+ bB+b
T
2
X
EM
 
I t=Bð Þ;
ð8Þ
where b0 is an intercept term, b1 is a vector of coeffi-
cients for prognostic variables, bB is the relative effect of
treatment B compared to A at X= 0, b2 is a vector of
coefficients for effect modifiers XEM (a subvector of the
full covariate vector X), and mt(AB) Xð Þ is the expected out-
come of an individual assigned treatment t with covariate
values X, which is transformed onto a chosen linear pre-
dictor scale with link function g ð Þ.
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The model in equation (8) is a more general form of
that given by Ishak et al.7, which does not include any
effect modifier terms. The STC literature advocates
forming indirect comparisons directly on the natural out-
come scale with g ð Þ the identity link in equation (4) or
(5); however, this leads to scale conflicts10 if the same
link is not used in the outcome model (8) (see the follow-
ing section on the importance of scale). Y^A(AC) and Y^B(AC)
may be predicted from the outcome regression by
substituting in mean covariate values to obtain
Y^A(AC)= g
1ðb^0+ b^
T
1
X(AC)Þ and Y^B(AC)= g
1ðb^0+
b^
T
1
X(AC)+ b^B+ b^
T
2
X
EM
(AC)Þ. These estimators are systema-
tically biased whenever g ð Þ is not the identity function,
because the mean outcome depends on the full distribu-
tion of the covariates and not just their mean.7 Instead
of substituting in mean covariate values in this case,
Ishak et al. suggest that estimates are obtained by first
drawing samples from the joint covariate distribution in
the AC trial and then averaging over the predicted out-
comes based on the regression model. This simulation
approach, however, inflates uncertainty of the relative
effect estimates.
Standard tools for model checking (such as AIC/DIC,
examining residuals, among others) may be used when
constructing the outcome model in the AB trial; however
(as with MAIC), additional assumptions are required to
predict absolute outcomes in the AC population, which
are difficult to test with the limited data available.
Overview of Assumptions Made by Different
Methods
It is critical to note that unanchored indirect comparisons
require much stronger assumptions than anchored indi-
rect comparisons. The assumptions required by different
forms of population-adjusted indirect comparisons are
summarized in Table 1.
A standard indirect comparison or (fixed effect) net-
work meta-analysis assumes ‘‘constancy of relative
effects’’ on the linear predictor scale, meaning that the
expected relative C v. A effect in the AC trial is identical
to that which would be expected in the AB trial. This
requires that any and all effect modifiers are balanced
between the 2 trial populations.
Anchored forms of population-adjusted indirect com-
parisons rely on ‘‘conditional constancy of relative
effects,’’ typically on the natural outcome scale. This
means that the relative treatment effects are assumed
constant between studies at any given level of the effect
modifiers, so there is no imbalance of unobserved effect
modifiers between the 2 trial populations. This is quite a
strong assumption but considerably less strong than the
constancy of relative effects assumption required for a
standard indirect comparison.
Unanchored forms of population-adjusted indirect
comparisons make the much stronger assumption of
‘‘conditional constancy of absolute effects.’’ This means
that the absolute treatment effects are assumed constant
at any given level of the effect modifiers and prognostic
variables, and all effect modifiers and prognostic vari-
ables are required to be known. This is a far more
demanding assumption than either constancy or condi-
tional constancy of relative effects, and widely accepted
to be very hard to meet.
The assumptions of internal validity and some form
of constancy are sufficient in the scenario where, despite
not having access to IPD on the AC trial, sufficient infor-
mation on the joint covariate distribution is available. In
practice, even this level of detail is unlikely, as published
trials frequently report only details of the marginal cov-
ariate distributions (e.g., mean/median and standard
deviation for continuous covariates, or proportion of
individuals with a binary/categorical trait). Additional
assumptions are therefore required: either that the true
outcome model does not depend on the correlations
between covariates, or that the missing correlations in
the AC trial may be imputed from those observed in the
AB trial.10
The Importance of Scale and its Relation to
Effect Modification
The standard practice for indirect comparisons, in com-
mon with standard methods of meta-analysis, is that they
are made on a pre-specified transformed scale (e.g., on
the log scale for odds ratios and risk ratios), rather than
on the natural outcome scale;1,3 to aid interpretation or
for the purposes of a cost effectiveness analysis, the
resulting estimates are back-transformed onto the natu-
ral scale. The reasons for this choice include approximate
normality and the stabilization of variance. Critically, for
indirect comparisons, effects are assumed to be additive
and linear on the transformed scale.
Effect modifier status is scale-specific,33 and the status
of a variable as an effect modifier on one scale does not
imply (either positively or negatively) the effect modifier
status on any other scale. MAIC and STC, as currently
practiced, are typically carried out on the natural out-
come scale, regardless of the conventional linear predic-
tor scale, so that variables that are effect modifiers in a
standard indirect comparison might not be in MAIC/
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Table 1 Assumptions Made by Different Methods for Indirect Comparisons
Method
Assumptions Made
Standard Indirect
Comparison, NMA
Network
Meta-regressiona
Unanchored
MAIC
Anchored
MAIC
Unanchored
STC
Anchored
STC
Constancy
Constancy of absolute effects N N N N N N
Conditional constancy
of absolute effects
N N Y
Typically on
natural outcome
scale.
N Y
Typically on natural
outcome scale.
N
Constancy of
relative effects
Y
On linear predictor
scale. For RE NMA
relaxed to constancy
in expectation.
N N N N N
Conditional constancy
of relative effects
N Y
On linear
predictor
scale.
N Y
Typically on
natural outcome
scale.
N Y
Typically on
natural
outcome scale.
Shared effect modifiers N/A Y
On linear predictor scale.
Not required if IPD are
available on both studies.
Nb Nb Nb Nb
aThe assumptions set out here are applicable to all forms of network meta-regression with varying combinations of IPD and aggregate data (both studies IPD, both studies
aggregate data, one IPD and one aggregate), with the exception of the shared effect modifier assumption which is not required if IPD are available on both studies.
bThe shared effect modifier assumption is not required, but may be additionally assumed in order to present estimates for another target population.
2
0
5
STC, and vice versa. Furthermore, forming the indirect
comparison on a different scale to that used for the out-
come model in STC results in serious issues due to the
conflicting scales: linearity and additivity cannot hold on
both scales, the definition of effect modifiers is obscured,
and the subsequent indirect comparison is uninterpreta-
ble. The choice of an appropriate scale is therefore criti-
cal, and should be made using biological and clinical
knowledge.34 Moreover, where a standard scale exists
for a given outcome upon which additivity is commonly
accepted, the use of an alternative scale is hard to justify.
In a decision-making context, the possibility of effect
modification has to be handled carefully, not least
because a treatment that is cost-effective at one value of
the effect modifier might not be at another. Guidelines
on methods recommend that effect modifiers must be
pre-specified and clinically plausible, and that supporting
evidence must be provided from a thorough review of
the subject area or from expert clinical opinion (see
Section 5.2.7 of the NICE Methods Guide,35 and ISPOR
guidance36).
Calibrating Population-Adjusted Estimates to
The Correct Target Population
The premise of both MAIC and STC is that the treat-
ment effect depends on the population. It is therefore
not sufficient to use MAIC or STC to generate an
‘‘unbiased’’ comparison in just any population; they are
only useful for decision making if they can produce a fair
comparison in the target population for the decision. In
general, the target population should be a cohort or reg-
istry study population relevant to the clinical decision,
which is unlikely to match the population of the AC trial.
However, MAIC and STC, as currently proposed, are
unable to achieve estimates in any population other than
that of the AC study.
To allow relative treatment effects to be projected into
any target population, we propose that an additional
assumption is made, known as the ‘‘shared effect modi-
fier assumption.’’ The shared effect modifier assumption
applies to a set of active treatments T , and states that 1)
the effect modifiers of all treatments in T are the same,
and 2) the change in treatment effect caused by each
effect modifier is the same for all treatments in T . This
assumption is not required for MAIC or STC as cur-
rently used. However, if deemed reasonable, it may be
leveraged to produce indirect comparisons in any given
target population. For example, if the shared effect
modifier assumption holds for treatments B and C, then
the estimated dBC relative treatment effect (whether
obtained using anchored or unanchored MAIC/STC)
will be applicable to any population. In general, we make
use of the relationship
dtu(P)= dtu(Q) 8t, u 2 T ð9Þ
for any 2 populations P and Q and for a set of treatments
T for which the shared effect modifier assumption holds.
Mathematical proof and examples are provided in
Appendix A. The shared effect modifier assumption is
evaluated on a clinical and biological basis; treatments in
the same class (i.e., sharing biological properties or mode
of action) are more likely to satisfy the shared effect
modifier assumption than those from different classes.
Recommendations for The Use of Population-
Adjusted Indirect Comparisons
The exact properties of population adjustment methodol-
ogies, such as MAIC and STC, in anchored and unan-
chored forms and their performance relative to standard
indirect comparisons can only be properly assessed by a
comprehensive simulation exercise. For this reason, we
do not express preference for any particular population
adjustment method. However, based on general princi-
ples, we can draw some useful conclusions about the role
of population-adjusted estimates of treatment effects,
including the types proposed by MAIC and STC, in sub-
missions to reimbursement agencies.
The recommendations in Table 2 and reporting guide-
lines in Appendix B are intended to promote reproduci-
bility, consistency, and transparency in the use of
population adjustment methods, whilst minimizing bias
and maximizing precision. A further desirable property is
that, if there were no effect modifiers, no adjustment
would occur: the estimates would be expected to be
exactly those produced by standard indirect comparison.
Appendix C provides flow charts summarizing these rec-
ommendations, and describing the process of selecting a
method for indirect comparison, undertaking the analy-
sis, and presenting the results.
Recommendations 1 to 3 are concerned with choosing
and justifying an appropriate form of population-
adjusted indirect comparisons over a standard indirect
comparison. Since unanchored comparisons make much
stronger assumptions than anchored comparisons, recom-
mendation 1 is that the latter should always be preferred.
For anchored comparisons, recommendation 2 requires
that a priori evidence of effect modifier status is provided,
along with evidence of substantial imbalance; this stems
from established guidance on effect modification.35,36
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Unanchored comparisons cannot rely on randomization
and thus are problematic (see the overview of assumptions
above). Recommendation 3 for unanchored comparisons
therefore calls for evidence of predictive accuracy for abso-
lute outcomes, and an estimate of residual bias due to unac-
counted for covariates, without which the amount of bias is
unknown but is likely to be substantial, and could even
exceed the magnitude of treatment effects being estimated.
Recommendation 4 ensures that bias is minimized
whilst controlling standard error. For anchored indirect
comparisons performed via population reweighting
methods (e.g., MAIC), all effect modifiers should be
adjusted for, whether in imbalance or not, to ensure bal-
ance and reduce bias. To avoid loss of precision due to
over-matching, purely prognostic variables should not be
adjusted for, as they do not affect the estimated relative
treatment effect. For anchored indirect comparisons per-
formed via outcome regression methods (e.g., STC), all
effect modifiers in imbalance should be adjusted for to
reduce bias. The inclusion of additional prognostic vari-
ables and effect modifiers in the model can result in a
gain in precision of the estimated treatment effect if the
variable accounts for a substantial degree of variation in
the outcome, but will not reduce bias any further. For an
unanchored indirect comparison, reliable predictions of
absolute outcomes are required; therefore, population
adjustment methods should adjust for all effect modifiers
and prognostic variables.
Recommendation 5 is to choose an appropriate linear
predictor scale for the adjustment and subsequent indi-
rect comparison in line with general modelling prac-
tice,35,37 avoiding scale conflicts (see the above section
on the importance of scale). If a scale is chosen that dif-
fers from what is usually used in existing literature for
that outcome and condition, thorough justification must
be given.
As noted in the previous section, population adjust-
ment methods are only useful for decision making if they
can produce estimates for the appropriate target popula-
tion; recommendation 6 makes this explicit, and the
shared effect modifier assumption defined above may be
utilized if appropriate.
Further detail on each of the recommendations may
be found in NICE DSU Technical Support Document
18.10
Discussion
The rationale for employing population adjustment
stems principally from 2 scenarios: 1) connected, com-
parative evidence is available but standard synthesis
methods are deemed inappropriate due to an imbalance
in suspected effect modifiers; or 2) no connected evidence
is available, or comparisons are required involving
single-arm studies. In this paper, we focused on a simple
2-study indirect comparison; however, in principle, the
Table 2 Recommendations for the Use of Population-Adjusted Indirect Comparisons
Recommendation 1: When connected evidence with a common comparator is available, a population-adjusted anchored indirect
comparison may be considered. Unanchored indirect comparisons may only be considered in the absence of a connected
network of randomized evidence, or where there are single-arm studies involved.
Recommendation 2: Submissions using population-adjusted analyses in a connected network need to provide evidence that they
are likely to produce less biased estimates of treatment differences than could be achieved through standard methods.
(a) Evidence must be presented that there are grounds for considering one or more variables as effect modifiers on the
appropriate transformed scale. This can be empirical evidence or an argument based on biological plausibility.
(b) Quantitative evidence must be presented that population adjustment would have a material impact on relative effect
estimates due to the removal of substantial bias.
Recommendation 3: Submissions using population-adjusted analyses in an unconnected network need to provide evidence that
absolute outcomes can be predicted with sufficient accuracy in relation to the relative treatment effects, and present an estimate
of the likely range of residual systematic error in the ‘‘adjusted’’ unanchored comparison.
Recommendation 4: The following variables should be adjusted for in a population-adjusted analysis:
(a) For an anchored indirect comparison, propensity score weighting methods should adjust for all effect modifiers (in
imbalance or not) but no prognostic variables. Outcome regression methods should adjust for all effect modifiers in
imbalance, and any other prognostic variables and effect modifiers that improve model fit.
(b) For an unanchored indirect comparison, both propensity score weighting and outcome regression methods should adjust
for all effect modifiers and prognostic variables to reliably predict absolute outcomes.
Recommendation 5: Indirect comparisons should be carried out on the linear predictor scale, with the same link functions that
are usually employed for those outcomes.
Recommendation 6: The target population for any treatment comparison must be explicitly stated, and population-adjusted
estimates of the relative treatment effects must be generated for this target population.
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methods and recommendations are generalizable to
situations where multiple studies are available for each
comparison or involving larger treatment networks. This
is a clear area for further research.
As with standard methods for indirect comparison1
and network meta-analysis,3 population-adjusted indi-
rect comparisons assume internal validity of the included
studies. An appropriately well-designed randomized
study is expected to balance the distributions of both
observed and unobserved prognostic variables and effect
modifiers between arms. Further research is necessary to
investigate methods for adjusting for within-study cov-
ariate imbalance, and other issues with internal validity,
such as lack of blinding.
By definition, the presence of effect modification means
that relative treatment effects may differ between popula-
tions and, as a result, different decisions could be reached in
different populations. MAIC and STC apply propensity
score reweighting and outcome regression to produce an
indirect comparison in the aggregate data population, typi-
cally that of a competitor’s study, which is unlikely to match
the decision target population. If the competitor was to use
its IPD and run the analysis the other way around, appar-
ently contradictory results could be obtained. This has
already arisen in practice, with 2 MAIC analyses from com-
peting manufacturers comparing treatments for ankylosing
spondylitis.38,39 Each manufacturer had IPD available on
their own study and used MAIC to form a comparison in
their competitor’s study population, and each obtained
opposing results in favor of their own treatment. With a
decision target population in mind, however, we note that
the real conflict lies not in the different results produced by
the 2 MAICs but in deciding which of the 2 study popula-
tions better represents the decision target population.
Ironically, each company is left in the position of implicitly
assuming that their competitor’s trial is more representative
of the decision target population than their own. We have
shown that the shared effect modifier assumption, if justi-
fied, may be used to transport indirect comparisons into the
target population for the decision without pleading to repre-
sentativeness. Methods that relax the shared effect modifier
assumption, or attempt to validate it, are areas for further
research.
Much of the literature on unanchored MAIC and
STC acknowledges the possibility of residual bias due
to unobserved prognostic variables and effect modi-
fiers;40–44 however, it is not made clear that the accuracy
of the resulting estimates is entirely unknown, because
there is no analysis of the potential magnitude of residual
bias, and hence no idea of the degree of error in the
unanchored estimates. It is, of course, most unlikely that
systematic error has been eliminated. Hoaglin,45,46 in a
critique of an unanchored comparison47 based upon a
matching approach similar to MAIC, remarked that,
without providing evidence that the adjustment compen-
sates for the missing common comparator arms and the
resulting systematic error, the ensuing results ‘‘are not
worthy of consideration.’’ If unanchored forms of popu-
lation adjustment are to be presented, it is essential that
submissions to reimbursement agencies include informa-
tion on the likely bias resulting from unobserved prog-
nostic factors and effect modifiers distributed differently
in the trials. The way in which residual systematic error
is quantified is an area that requires further research.
A potential and oft-cited advantage of MAIC is that
it is perceived to be ‘‘scale-free’’, as the definition of the
weighting model does not require any fixed outcome
scale to be chosen.6,7 Although it is true that the
reweighting procedure makes no scale assumptions, the
subsequent indirect comparison does assume additivity
on a specific scale, and therefore neither MAIC nor STC
are ‘‘scale-free’’ in this important sense.
Setting aside their failure to generate coherent
population-adjusted estimates for the chosen target pop-
ulation, MAIC and STC also give very considerable lee-
way to investigators to choose anchored or unanchored
approaches, and to pick and choose variables for adjust-
ing. In the interests of transparency and consistency, and
to ensure equity for patients and a degree of certainty for
those making submissions to reimbursement agencies, it
is essential to regularize how and under what circum-
stances these procedures should be used, and which addi-
tional analyses should be presented to support their use
and assist interpretation. We believe that the recommen-
dations set out here go a long way toward meeting these
objectives.
MAIC and STC are not the only approaches to popu-
lation adjustment. One alternative stems from network
meta-regression, with regression models defined at both
the individual level and at the study level.48–53 If the
study level model is an integration of the individual level
model over the study population,50,52,53 then aggregation
bias is avoided;4,10,54 however, at present, these types of
models have only been derived for simple scenarios with
binary covariates.10,50 Attractively, these methods are
naturally generalizable to connected networks of any
size, and they reduce to the gold standard IPD network
meta-regression if IPD are available for all trials. Doubly
robust techniques that combine both reweighing and
regression adjustment are also plausible, and have been
described for the case when full IPD are available by
Zhang et al.24 We would expect these alternatives to have
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similar properties to MAIC and STC in both anchored
and unanchored scenarios, and the recommendations
made in the last section are applicable to population
adjustment methods in general; for a more detailed dis-
cussion, see NICE DSU Technical Support Document
18.10 Further research is needed to assess all available
methods alongside MAIC and STC; in particular,
to examine their properties and robustness to breakdown
of assumptions, with varying levels of data availability,
through thorough simulation studies.
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